Thus, we suggest that the levels of mtDNA and PD-L1 in/on EVs in patients with oral cancer may function as a potential diagnostic biomarker for anti-PD-L1 immunotherapy. The gene discussed is CD274; the disease is lip and oral cavity carcinoma.